www.fdanews.com/articles/179182-pfizer-ends-global-development-of-bococizumab
Pfizer Ends Global Development of Bococizumab
November 7, 2016
Pfizer has discontinued the global clinical development program for bococizumab, its investigational proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i).
Pfizer has observed an emerging clinical profile that includes an unanticipated reduction of low-density lipoprotein cholesterol (LDL-C) over time, as well as a higher level of immunogenicity and higher rate of injection-site reactions with bococizumab than shown with the other agents in this class.
With the decision to discontinue bococizumab development, Pfizer will halt two ongoing cardiovascular outcome studies.